8-K filing — Summit Therapeutics Inc. (SMMT)
Filed: 2026-09-15 AccNo: 0001599298-26-000081 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed
Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is Summit Therapeutics Stock Gaining Monday?
Summit partner Akeso reports 30.8-month median OS for ivonescimab vs 22.6 for pembrolizumab in lung cancer trial. SMMT up over 6%.
Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows
Ivonescimab Reduced the Risk of Death by 27% Compared to PembrolizumabHARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 MonthsPD-L1 High Expression Subgroup: Hazard Ratio = 0.58Summit is Conducting